News | February 19, 2026
Zydus introduces ANYRA (Aflibercept 2 mg) for advanced retinal disease treatment
ANYRA is India’s first indigenously developed Aflibercept 2 mg biosimilar
ANYRA is India’s first indigenously developed Aflibercept 2 mg biosimilar
All pending litigation between Biocon Biologics, Regeneron, and Bayer will be dismissed
Demonstrates vision gains with extended treatment intervals in retinal vein occlusion
The approval of YESAFILI marks Biocon Biologics’ expansion into the ophthalmology therapeutic area in the United States
Yesafili, received marketing authorization approval from the European Commission for the European Union
The centralized marketing authorization granted by the EC is valid in all EU Member States as well as in the European Economic Area (EEA) countries Iceland, Liechtenstein and Norway
Aflibercept is the second biosimilar product that has entered the clinical trial phase after biosimilar Adalimumab
The trial, dubbed MALBEC, marks the first in a broader late-phase development push for MK-8748, with a second NVAMD study expected to begin later this year
Eylea 2mg (intravitreal aflibercept injection) is an anti-VEGF therapy that blocks a protein responsible for abnormal blood vessel growth and leakage in the retina
It promises fewer injections for vision loss patients
Subscribe To Our Newsletter & Stay Updated
